Askbio Inc

This study tests a one-time gene therapy called AB-1002, given directly into the heart arteries, for people with advanced heart failure (NYHA Class III). The goal is to see if it can improve heart function, reduce symptoms, and lower the risk of death or hospitalization. About 15…

This study follows 150 people with early Parkinson's disease or Multiple System Atrophy (MSA) for up to 18 months. Researchers will measure changes in motor symptoms, quality of life, and biomarkers to better understand how these diseases progress. The goal is to gather informati…

This study follows 132 people with Parkinson's disease or multiple system atrophy who previously received the gene therapy AB-1005. Researchers will track safety and how well the treatment works over the long term. No new treatments are given; it's purely observational.